StockNews.AI
CLGN
StockNews.AI
14 days

COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR SECOND QUARTER FINANCIAL RESULTS

1. CollPlant will report Q2 financial results on August 20, 2025. 2. Company specializes in rhCollagen for tissue regeneration and medical aesthetics. 3. Developed innovative solutions for tissue repair and aesthetic markets. 4. In 2021, partnered with Allergan for global commercialization of fillers. 5. Focus on 3D bioprinting technology for organ manufacturing.

Earnings
+15.22%Current Return
VS
+0.23%S&P 500
$2.247908/05 07:11 AM EDTEvent Start
$2.5908/06 02:04 PM EDTLatest Updated
4m saved
Insight
Article

FAQ

Why Neutral?

Upcoming earnings announcement could influence market sentiment, historically results have mixed effects.

How important is it?

Financial results will inform investors about company growth and future direction, impacting stock price.

Why Short Term?

Near-term effects expected due to impending financial report; longer-term impact depends on performance.

Related Companies

ABBVALGNTGTX
, /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived, rhCollagen for tissue regeneration and medical aesthetics, today announced that it will report financial results for the second quarter on Wednesday, August 20, 2025, before the opening of the U.S. financial markets. About CollPlant CollPlant is a regenerative and aesthetic medicine company ushering in a new era of medical solutions with a focus on 3D bioprinting of tissues and organs, tissue repair and medical aesthetics. The Company's products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant-based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. In 2021, CollPlant entered into a development and global commercialization agreement for dermal and soft tissue fillers with Allergan, an AbbVie company, the global leader in the dermal filler market. For more information about CollPlant, visit http://www.collplant.com. Contacts: CollPlant:Eran RotemDeputy CEO & CFOTel: +972-73-2325600Email: [email protected]  Investors:Daniel FerryManaging DirectorLifeSci Advisors, LLC[email protected]  Logo: https://mma.prnewswire.com/media/2217353/CollPlant_Logo.jpg SOURCE CollPlant WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In

Related News